Form 4: OnKure Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Nicholas A Saccomano, President and CEO and a Director of OnKure Therapeutics, Inc., reported multiple transactions in common stock on August 7, 2026.
Summary
- Grant/award: acquired 150,000 Employee Stock Option (right to buy) on August 7, 2026; holds 150,000 after (Direct).
- Disposition to the issuer: disposed of 2,359 Employee Stock Option (right to buy) on August 7, 2026 (Direct).
- Grant/award: acquired 2,359 Employee Stock Option (right to buy) on August 7, 2026; holds 2,359 after (Direct).
- Disposition to the issuer: disposed of 1,485 Employee Stock Option (right to buy) on August 7, 2026 (Direct).
- Grant/award: acquired 1,485 Employee Stock Option (right to buy) on August 7, 2026; holds 1,485 after (Direct).
- Disposition to the issuer: disposed of 8,449 Employee Stock Option (right to buy) on August 7, 2026 (Direct).
- Grant/award: acquired 8,449 Employee Stock Option (right to buy) on August 7, 2026; holds 8,449 after (Direct).
- Disposition to the issuer: disposed of 16,898 Employee Stock Option (right to buy) on August 7, 2026 (Direct).
- Grant/award: acquired 16,898 Employee Stock Option (right to buy) on August 7, 2026; holds 16,898 after (Direct).
- Disposition to the issuer: disposed of 542,232 Employee Stock Option (right to buy) on August 7, 2026 (Direct).
- Grant/award: acquired 542,232 Employee Stock Option (right to buy) on August 7, 2026; holds 542,232 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Nicholas A Saccomano — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-07 | Grant/award | Employee Stock Option (right to buy) | 150,000 | — | — | 150,000 |
| 2026-08-07 | Disposition to the issuer | Employee Stock Option (right to buy) | 2,359 | — | — | 0 |
| 2026-08-07 | Grant/award | Employee Stock Option (right to buy) | 2,359 | — | — | 2,359 |
| 2026-08-07 | Disposition to the issuer | Employee Stock Option (right to buy) | 1,485 | — | — | 0 |
| 2026-08-07 | Grant/award | Employee Stock Option (right to buy) | 1,485 | — | — | 1,485 |
| 2026-08-07 | Disposition to the issuer | Employee Stock Option (right to buy) | 8,449 | — | — | 0 |
| 2026-08-07 | Grant/award | Employee Stock Option (right to buy) | 8,449 | — | — | 8,449 |
| 2026-08-07 | Disposition to the issuer | Employee Stock Option (right to buy) | 16,898 | — | — | 0 |
| 2026-08-07 | Grant/award | Employee Stock Option (right to buy) | 16,898 | — | — | 16,898 |
| 2026-08-07 | Disposition to the issuer | Employee Stock Option (right to buy) | 542,232 | — | — | 0 |
| 2026-08-07 | Grant/award | Employee Stock Option (right to buy) | 542,232 | — | — | 542,232 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-07 | Grant/award (150,000 shares) |
| 2026-08-07 | Disposition to the issuer (2,359 shares) |
| 2026-08-07 | Grant/award (2,359 shares) |
| 2026-08-07 | Disposition to the issuer (1,485 shares) |
| 2026-08-07 | Grant/award (1,485 shares) |
| 2026-08-07 | Disposition to the issuer (8,449 shares) |
| 2026-08-07 | Grant/award (8,449 shares) |
| 2026-08-07 | Disposition to the issuer (16,898 shares) |
| 2026-08-07 | Grant/award (16,898 shares) |
| 2026-08-07 | Disposition to the issuer (542,232 shares) |
| 2026-08-07 | Grant/award (542,232 shares) |
Keywords
insider transaction, Form 4, OKUR, OnKure Therapeutics, Inc., neutral, Nicholas A Saccomano
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.